Biology is multi-layered and complex. Traditional experiments overlook significant information by only investigating one layer of life’s complexity. Multiomics removes guesswork to unlock a deeper understanding of complex issues. It explores multiple 'omes' — combinations of the genome, proteome, transcriptome, and epigenome — in one experiment.
Come and Join a Multiomics Day with CRLB-GMEL, sponsored by Illumina and Olink.
Let’s discover the power of Multiomics and learn how Multiomics can fuel your research breakthroughs.
Come and Join a Multiomics Day with CRLB-GMEL, sponsored by Illumina and Olink.
Let’s discover the power of Multiomics and learn how Multiomics can fuel your research breakthroughs.
Location
Alumni Memorial Building
1280 Main St W, Hamilton, On L8S 4L8
or
Virtual
1280 Main St W, Hamilton, On L8S 4L8
or
Virtual
Date & Time
September 27, 2022, 12:00 PM - 5:00 PM
Our Speakers
Michael Förster,
PhD, Scientific Director, Oncology and Rare Disease- Olink
Title: Targeted protein screening for biomarker discovery in health and disease.
Bio: Dr. Michael Forster.
As Director Oncology and Rare Diseases, Michael supports a portfolio of investigator-led studies that use Olink's proximity extension assay to identify new biomarkers for cancer, metabolic and infectious diseases.
Bio: Dr. Michael Forster.
As Director Oncology and Rare Diseases, Michael supports a portfolio of investigator-led studies that use Olink's proximity extension assay to identify new biomarkers for cancer, metabolic and infectious diseases.
Lisa Lock
PhD, Senior Sequencing Specialist- Illumina
Title: Illumina Technology and Application Updates: Fall 2022
Bio: Lisa obtained her PhD in biochemistry at McGill University. After focusing on cell signaling research as a post-doc fellow, she worked at Lorus Therapeutics as a research scientist and consultant. Prior to her current role, Lisa was a Field Application Scientist at Illumina for 11 years. She focused on providing customer training, as well as supporting customer experimental design and troubleshooting.
Bio: Lisa obtained her PhD in biochemistry at McGill University. After focusing on cell signaling research as a post-doc fellow, she worked at Lorus Therapeutics as a research scientist and consultant. Prior to her current role, Lisa was a Field Application Scientist at Illumina for 11 years. She focused on providing customer training, as well as supporting customer experimental design and troubleshooting.
Douglas D. Fraser
MD, PhD, FRCPC, Professor and Clinician Scientist, Western University
Title: Covid-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high precision disease management
Bio: Dr. Fraser received his MD/PhD in Physiology, Biophysics and Neuroscience at the University of Calgary and subsequently trained in Pediatrics (Queen’s University) and Critical Care Medicine (University of Ottawa). He joined Western University in 2003. Dr. Fraser’s research is focused on determining the epidemiology and cellular mechanisms underlying acquired brain injury in trauma, diabetic ketoacidosis and severe sepsis. With the arrival of SARS-CoV-2, Dr. Fraser’s laboratory immediately collected and analyzed COVID-19 biological samples (transcriptomics, metabolomics and proteomics). He has published 14 COVID-19 publications and holds 6 COVID-19 related patents. He was an invited international member of the NIH Workshop on COVID-19 Associated Coagulopathy (CAC; May 6-7, 2021) and an invited speaker at the US Human Proteome Organization meeting.
Bio: Dr. Fraser received his MD/PhD in Physiology, Biophysics and Neuroscience at the University of Calgary and subsequently trained in Pediatrics (Queen’s University) and Critical Care Medicine (University of Ottawa). He joined Western University in 2003. Dr. Fraser’s research is focused on determining the epidemiology and cellular mechanisms underlying acquired brain injury in trauma, diabetic ketoacidosis and severe sepsis. With the arrival of SARS-CoV-2, Dr. Fraser’s laboratory immediately collected and analyzed COVID-19 biological samples (transcriptomics, metabolomics and proteomics). He has published 14 COVID-19 publications and holds 6 COVID-19 related patents. He was an invited international member of the NIH Workshop on COVID-19 Associated Coagulopathy (CAC; May 6-7, 2021) and an invited speaker at the US Human Proteome Organization meeting.
Allison Boyd, PhD
phD, Research Associate
Dr. Mick Bhatia’s laboratory, McMaster University
Dr. Mick Bhatia’s laboratory, McMaster University
Title: High Resolution Profiling of Functionally Relevant Cells in Acute Myeloid Leukemia
Bio: Allison is a Research Associate in the laboratory of Dr. Mick Bhatia. She has a background in solid tumor biology (MSc, Trent University) and acute myeloid leukemia (PhD, McMaster University), with a focus on tumor-microenvironment interactions. She now works as part of an interdisciplinary team applying multi-omic technologies to better understand acute myeloid leukemia disease in clinical and pre-clinical settings.
Bio: Allison is a Research Associate in the laboratory of Dr. Mick Bhatia. She has a background in solid tumor biology (MSc, Trent University) and acute myeloid leukemia (PhD, McMaster University), with a focus on tumor-microenvironment interactions. She now works as part of an interdisciplinary team applying multi-omic technologies to better understand acute myeloid leukemia disease in clinical and pre-clinical settings.
Schedule
12:00 PM
Lunch
12:30 PM
Welcoming presentation by CRLB-GMEL
1:00 PM
Michael Förster, PhD
Targeted protein screening for biomarker discovery in health and disease.
Targeted protein screening for biomarker discovery in health and disease.
1:45 PM
Douglas D. Fraser, MD, PhD, FRCPC
Covid-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high precision disease management
Covid-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high precision disease management
2:45 PM
Coffee Break
3:00 pm
Lisa Lock, PhD, Senior Sequencing Specialist- Illumina
Illumina Technology and Application Updates: Fall 2022
Illumina Technology and Application Updates: Fall 2022
3:30 pm
Dr. Allison Boyd PhD
High Resolution Profiling of Functionally Relevant Cells in Acute Myeloid Leukemia
High Resolution Profiling of Functionally Relevant Cells in Acute Myeloid Leukemia
4:30 pm
Closing Presentation